SkinBioTherapeutics (AIM:SBTX), the AIM-listed life science business focused on skin health, expects to report revenue growth of approximately 20.5% to £4.7m for the year ended 30 June, up from £3.9m restated in the prior year.
The increase is driven largely by a full year's trading from Bio-Tech Solutions, which is expected to contribute £2.1m against £1.4m for nine months in FY25, an underlying rise of around 10% excluding intercompany sales. Earnings (adjusted EBITDA) loss is expected to narrow slightly to £1.6m from £1.7m restated, stated before £1.2m of exceptional costs tied to a forensic investigation, comprising £0.7m of direct investigation costs and £0.5m of other one-off legal and employment-related charges.
Cash fell to £1.5m at 30 June from £4.8m a year earlier, reflecting the EBITDA loss and exceptional items, though the Group says it holds sufficient reserves for current operations.
Alongside the update, Rachel Parsonage, appointed Interim CEO in March, and Alyson Levett, Interim Chair since June, have both agreed to take their roles on a permanent basis, with Levett continuing as interim Chair of the Audit & Risk Committee.
"She has provided stability and leadership during an exceptionally challenging period", said Levett of Parsonage's tenure.
Trading in the early months of FY27 has run ahead of management's internal expectations, with the Board prioritising revenue growth, reducing the underlying operating loss and preserving cash. The FY26 figures remain subject to audit review ahead of final results later in the year.
News Intelligence what this means for the company
SkinBioTherapeutics reported 20.5% revenue growth to £4.7m for FY26, driven by a full year of Bio-Tech Solutions contribution, while narrowing its adjusted EBITDA loss to £1.6m. The company permanently appointed its interim CEO and Chair after a forensic investigation that cost £1.2m in exceptional charges, but cash reserves fell sharply to £1.5m from £4.8m—a 69% decline that constrains runway despite management's claim of sufficient reserves for current operations.
Revenue growth and EBITDA loss narrowing are operationally positive, but the cash burn rate (£3.3m net cash outflow in one year against £1.6m adjusted EBITDA loss) signals that the company is consuming capital faster than headline losses suggest, raising questions about funding runway and the sustainability of the stated FY27 trading momentum without external capital.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
